Literature DB >> 10563193

Monitoring of interobserver agreement in nuclear atypia scoring of node-negative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol.

H Tsuda1, F Akiyama, M Kurosumi, G Sakamoto, T Watanabe.   

Abstract

BACKGROUND: In the NSAS-BC protocol, the nuclear atypia and mitotic counts are to be judged by pathologists at each participating hospital for assessing high-risk node-negative breast cancers. Therefore, maintenance of interobserver agreement in diagnosis at a higher level is mandatory during the period of patient entry.
METHODS: Individual collaborating pathologists originally evaluated the histological eligibility of 107 cases. Three panel pathologists determined consensus diagnoses and 29-37 collaborating pathologists determined modal diagnoses of these cases at three slide conference sessions. The original diagnoses were compared with the consensus and modal diagnoses to estimate the percentage of erroneous judgments.
RESULTS: The agreement rate in histological type and nuclear atypia score was 69% (74/107) between the original and consensus diagnoses, 76% (81/107) between the original and modal diagnoses and 86% (92/107) between the consensus and modal diagnoses. The strength of interobserver agreement at the slide conference sessions was moderate (0.447-0.535) by kappa statistics. The original, consensus and modal diagnoses were concordant in 71 cases (66%), but were discordant in 36. Of 35 invasive ductal carcinomas with discordant diagnoses, the discordance arose from the intermediate tumor nature in 15, multiple factors in 13 and erroneous diagnosis in seven (6.5%), if the characteristics of the tumor were judged from the percentage interobserver agreement per tumor at the slide conferences.
CONCLUSION: Nuclear atypia scoring given at individual hospitals on case entry was almost reproducible among the pathologists. Continuous efforts are needed to improve interobserver agreement and to decrease erroneous diagnosis for protocol eligibility.

Entities:  

Mesh:

Year:  1999        PMID: 10563193     DOI: 10.1093/jjco/29.9.413

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  Diagnosing breast cancer by using Raman spectroscopy.

Authors:  Abigail S Haka; Karen E Shafer-Peltier; Maryann Fitzmaurice; Joseph Crowe; Ramachandra R Dasari; Michael S Feld
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-22       Impact factor: 11.205

2.  Clinicopathological analysis in PTCL-NOS with CADM1 expression.

Authors:  Takeharu Kato; Hiroaki Miyoshi; Seiichiro Kobayashi; Noriaki Yoshida; Yoshitaka Imaizumi; Masao Seto; Kaoru Uchimaru; Yasushi Miyazaki; Koichi Ohshima
Journal:  Virchows Arch       Date:  2017-09-22       Impact factor: 4.064

3.  Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

Authors:  Kyoko Yorozuya; Toru Takeuchi; Miwa Yoshida; Yukako Mouri; Junko Kousaka; Kimihito Fujii; Shogo Nakano; Takashi Fukutomi; Kazuo Hara; Shu Ichihara; Yingsong Lin; Shogo Kikuchi
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-28       Impact factor: 4.553

4.  New criteria to predict tumor recurrence in invasive ductal carcinoma of the breast.

Authors:  Tadahiro Nozoe; Emiko Mori; Tomohiro Iguchi; Takahiro Ezaki
Journal:  Int Surg       Date:  2013 Oct-Dec

5.  Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.

Authors:  Manabu Futamura; Yasuko Nagao; Kazuhiro Ishihara; Makoto Takeuchi; Takumi Nakada; Yoshihiro Kawaguchi; Masayoshi Asano; Iwao Kumazawa; Takashi Shiroko; Kasumi Morimitsu; Ryutaro Mori; Masahito Nawa; Toshio Shimokawa; Kazuhiro Yoshida
Journal:  Breast Cancer       Date:  2017-01-03       Impact factor: 4.239

6.  Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol.

Authors:  H Tsuda; F Akiyama; M Kurosumi; G Sakamoto; K Yamashiro; T Oyama; T Hasebe; K Kameyama; T Hasegawa; S Umemura; K Honma; T Ozawa; K Sasaki; H Morino; S Ohsumi
Journal:  Jpn J Cancer Res       Date:  2000-04

7.  Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.

Authors:  Hitoshi Tsuda; Masafumi Kurosumi; Futoshi Akiyama; Shinji Ohno; Shigehira Saji; Norikazu Masuda; Akihiko Shimomura; Nobuaki Sato; Shintaro Takao; Shozo Ohsumi; Yutaka Tokuda; Hideo Inaji; Toru Watanabe
Journal:  Breast Cancer       Date:  2022-04-18       Impact factor: 3.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.